ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
August 15 2022 - 8:25AM
ContraFect Corporation (Nasdaq:
CFRX), a clinical-stage biotechnology company focused on
the discovery and development of direct lytic agents (DLAs),
including lysins and amurin peptides, as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
announces today the publication of a manuscript in the Journal of
Bone and Joint Infection, a leading peer-reviewed journal dedicated
to the study of osteo-articular and soft-tissue infections. This
manuscript presents the results from a study evaluating the
activity of exebacase or the CF-296 lysin in a preclinical rabbit
model of implant-associated methicillin-resistant Staphylococcus
aureus (MRSA) osteomyelitis. These results demonstrate that the
local administration of either lysin to the affected bone, in
addition to systemic antibiotics, reduced MRSA counts in the bone
and on implants compared with control animals. Notably, the
administration of exebacase alone, without systemic antibiotics,
resulted in significant reductions in MRSA counts compared to
controls. Furthermore, either exebacase or CF-296, used in addition
to systemically administered daptomycin, also resulted in
significant reduction in MRSA counts on infected implants compared
to daptomycin alone.
“This new research data demonstrate the
potential to prosecute exebacase in a new clinical study of
patients with chronic or recurrent prosthetic joint infections
caused by MRSA or Staphylococcus epidermidis (S. epidermidis),
which has also been evaluated across fifteen compassionate use
cases in patients at Hôspices Civils de Lyon in Lyon, France,”
stated Roger J. Pomerantz, M.D., ContraFect’s President, Chief
Executive Officer, and Chairman. “We remain resolute in the
development of these new modality treatments for patients suffering
from osteomyelitis and prosthetic joint infections, which are
particularly difficult-to-treat with current standard of care joint
removal and reimplantation, which may lead to further disability,
and where novel treatments are greatly needed,” added Dr.
Pomerantz.
The company continues to evaluate exebacase for
potential clinical development targeting S. aureus and S.
epidermidis prosthetic joint infections and to consider CF-296 for
further preclinical studies and potential future clinical
development.
About ContraFect:
ContraFect is a biotechnology company focused on
the discovery and development of DLAs, including lysins and amurin
peptides, as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our platform of DLAs, which include lysins and amurin
peptides. Lysins are a new class of DLAs which are recombinantly
produced antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are a novel class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including P. aeruginosa, Acinetobacter
baumannii, and Enterobacter species. We believe that the
properties of our lysins and amurin peptides will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa, which can cause serious infections such as
bacteremia, pneumonia and osteomyelitis. We have completed a Phase
2 clinical trial for the treatment of Staph
aureus bacteremia, including endocarditis, with our lead lysin
candidate, exebacase, which is the first lysin to enter clinical
studies in the U.S. Exebacase was granted Breakthrough Therapy
designation by the FDA for the treatment of MRSA bloodstream
infections, including right-sided endocarditis, when used in
addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on
Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding the manuscript, its
publication and results of the study, statements made by Dr.
Pomerantz, ContraFect’s ability to discover and develop DLAs as new
medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, the development of exebacase or
CF-296, whether ContraFect will address life-threatening infections
using therapeutic candidates from its DLA platform, whether lysins
are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, whether amurins are a
novel class of DLAs which exhibit broad-spectrum activity against a
wide range of antibiotic-resistant Gram-negative pathogens, and
whether the properties of ContraFect’s lysins and amurins will make
them suitable for targeting antibiotic-resistant organisms, such as
MRSA and P. aeruginosa. Forward-looking statements are
statements that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including the occurrence of any adverse events related to
the discovery, development and commercialization of ContraFect’s
product candidates such as unfavorable clinical trial results,
insufficient supplies of drug products, the lack of regulatory
approval, or the unsuccessful attainment or maintenance of patent
protection and other important risks detailed under the caption
“Risk Factors” in ContraFect's Quarterly Report on Form 10-Q for
the quarter ended June 30, 2022 and its other filings with the
Securities and Exchange Commission. Actual results may differ from
those set forth in the forward-looking statements. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect
CorporationEmail: mmessinger@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024